Tatsis Ourania, EVP and Chief Regulatory & Quality Officer, has demonstrated a consistent pattern of selling activity across two companies—Vertex Pharmaceuticals (VRTX) and Verve Therapeutics (VERV)—with no recorded purchases in SEC filings. Of the 43 reported transactions, all were sales or awards, totaling over $30.1 million in sell value. The vast majority of activity centers on VRTX, with recent sales in February 2026 alone exceeding $4.8 million, including a $749,985 transaction on February 13 and a $789,274 sale on February 24. Earlier transactions, such as a $2.14 million sale on January 7, 2026, and a $2.02 million sale in December 2025, reinforce this trend. Filings also indicate periodic stock awards (coded "A") and dispositions (coded "D") for VERV, though these carried no reported monetary value.
The absence of buy transactions suggests Ourania has been systematically reducing exposure to VRTX, with sales occurring in clusters—such as multiple disposals in February 2026, including a $1.85 million transaction on February 13 and a $1.1 million sale on February 17. The frequency and size of these sales, often paired with stock awards or option exercises (coded "F"), indicate a recurring liquidation strategy rather than sporadic divestment. While the reasons behind the sales are undisclosed, the data reflects a clear directional bias toward reducing holdings in Vertex Pharmaceuticals over time.
AI-assisted summary